Capricor Therapeutics, Inc. Appoints Anthony Bergmann, as Chief Financial Officer, Effective January 1, 2018
December 22, 2017 at 09:04 pm
Share
Capricor Therapeutics, Inc. appointed Anthony Bergmann, as Chief Financial Officer, effective January 1, 2018. Mr. Bergmann has been serving as the company's Vice President-Finance and Treasurer since 2013. Mr. Bergmann joined Capricor, Inc., now a wholly-owned subsidiary of the company, in 2011 as the Director of Finance, where he served until November 2013. Prior to joining the Company, Mr. Bergmann worked in accounting and finance for several small to mid-size companies. On December 20, 2017, Leland Gershell gave notice of his resignation as Chief Financial Officer of the company, effective January 1, 2018. In connection with his resignation.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
CAPRICOR THERAPEUTICS, INC. 
